Fragment-Based Drug Discovery for RNA Targets
- PMID: 34101375
- DOI: 10.1002/cmdc.202100324
Fragment-Based Drug Discovery for RNA Targets
Abstract
Rapid development within the fields of both fragment-based drug discovery (FBDD) and medicinal targeting of RNA provides possibilities for combining technologies and methods in novel ways. This review provides an overview of fragment-based screening (FBS) against RNA targets, including a discussion of the most recently used screening and hit validation methods such as NMR spectroscopy, X-ray crystallography, and virtual screening methods. A discussion of fragment library design based on research from small-molecule RNA binders provides an overview on both the currently limited guidelines within RNA-targeting fragment library design, and future possibilities. Finally, future perspectives are provided on screening and hit validation methods not yet used in combination with both fragment screening and RNA targets.
Keywords: RNA; drug discovery; fragments; screening.
© 2021 Wiley-VCH GmbH.
References
-
- R. Moumné, M. Catala, V. Larue, L. Micouin, C. Tisné, Biochimie 2012, 94, 1607-1619.
-
- J. Sztuba-Solinska, G. Chavez-Calvillo, S. E. Cline, Bioorg. Med. Chem. 2019, 27, 2149-2165.
-
- T. Wehler, R. Brenk, in RNA Therapeutics. Topics in Medicinal Chemistry (Ed.: A. L. Garner), Springer International Publishing, 2017, pp. 47-77.
-
- H. S. Haniff, L. Knerr, J. L. Chen, M. D. Disney, H. L. Lightfoot, SLAS Discov. 2020, 25, 869-894.
-
- C. M. Connelly, M. H. Moon, J. S. Schneekloth, Cell Chem. Biol. 2016, 23, 1077-1090.